retatrutide triple agonist weight loss trial Today we shared new results on retatrutide, an investigational, first Retatrutide 30mg | 20-Vial Kit

Semaglutide-related nausea, vomiting, and diarrhea all contribute to fluid loss

In STEP-1 (semaglutide), lean mass decreased by ~9.7% while fat mass fell by ~19.3%, with the proportion of lean mass increasing by ~3 percentage points (35)

pmid:21177976 48

Waiting more than 30 minutes to eat may increase the absorption of RYBELSUS

To learn more about boosting your weight loss efforts with LipoC and NAD+ injections, we invite you to schedule an appointment at CareOne Internal Medicine and Primary Care in Houston or Katy, Texas, today

In March 2024, wegovy, a semaglutide or GLP1, was approved to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or obese